سعر ليفمير 100 وحدة دولية / مل 5 اقلام معبأة للحقن 2022

Levemir 100 i.u./ml 5 flexpen: insulin detemir 100 units/ml, 5 pre-filled pens (FlexPen), 3 ml each (Novo Nordisk); long-acting basal insulin for subcutaneous injection.

• Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.Population: Adults, adolescents and children 1 year and olderEuropean Medicines Agency (EMA)

• Very common: hypoglycaemia (major hypoglycaemia in about 6% of patients in trials). Common: injection site reactions (pain, redness, hives, inflammation, bruising, swelling, itching), more frequent than with human insulin and usually transient.International label, same product · European Medicines Agency (EMA)
• Uncommon: allergic reactions, refraction disorders, diabetic retinopathy, lipodystrophy; rare: painful peripheral neuropathy; very rare: anaphylaxis; not known: cutaneous amyloidosis.International label, same product · European Medicines Agency (EMA)

• Hypersensitivity to insulin detemir or any of the excipients.International label, same product · European Medicines Agency (EMA)
• Use during episodes of hypoglycaemia (US label lists this as a contraindication).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypoglycaemia is the most frequent adverse reaction; it can follow a missed meal, unplanned strenuous exercise or a dose too high for requirements. Warning symptoms may change after improved control, with longstanding diabetes or after switching insulin.International label, same product · European Medicines Agency (EMA)
• Inadequate dosing or stopping treatment, especially in type 1 diabetes, may cause hyperglycaemia and diabetic ketoacidosis.International label, same product · European Medicines Agency (EMA)
• Switching to another type or brand of insulin must be done under strict medical supervision and may require dose changes; illness, infection and fever usually increase insulin requirements.International label, same product · European Medicines Agency (EMA)

• Oral antidiabetics, GLP-1 receptor agonists, MAOIs, beta-blockers, ACE inhibitors, salicylates, anabolic steroids, sulphonamidesMay reduce insulin requirements.European Medicines Agency (EMA)
• Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone, danazolMay increase insulin requirements.European Medicines Agency (EMA)
• Beta-blockersMay mask symptoms of hypoglycaemia.European Medicines Agency (EMA)

• Post-marketing data from more than 4,500 pregnancy outcomes do not indicate an increased risk of malformations or feto/neonatal toxicity; treatment can be considered during pregnancy if clinically needed, with intensified glucose control and monitoring.International label, same product · European Medicines Agency (EMA)
• Unknown whether insulin detemir is excreted in milk; no metabolic effects on the breastfed infant are anticipated (peptide digested in the gut). Breastfeeding women may need dose and diet adjustment.International label, same product · European Medicines Agency (EMA)

English text not available for this section.